Brookfield, CT


Representing: Patients, Caregivers, and Patient Advocates

J. Russell Teagarden is a senior healthcare practitioner, executive, and educator with a broad base of experience from positions in clinical pharmacy practice, clinical research, university teaching, medical communication and publishing, pharmacy benefit management, nonprofit patient advocacy, and executive leadership. These experiences provided a deep understanding of how health care standards are developed and translated into clinical practice, how the many and varied dimensions of domestic and international health care systems operate and affect individuals, populations, and institutions, how well current health care professions education and training programs prepare students for their professional roles, and how illness figures in the human condition. He holds a BS in Pharmacy, an MA in Research Methods, and a Doctorate in Medical Humanities, completed a residency in hospital pharmacy at Northwestern University Medical Center, and was a visiting scholar at the National Institutes of Health Bioethics Department.

Teagarden served as a member of the Advisory Panel on Rare Disease from April 2013 - September 2015.

Conflicts of Interest

As of December 17, 2014:

  • California Health Benefits Review Program National Advisory Council, Member
  • Deans Advisory Council, University of Illinois College of Pharmacy, Member
  • Keck Graduate Institute Advisory Council, Member
  • Keck Graduate Institute School of Pharmacy Advisory Board, Member
  • Medicare Evidence Development & Coverage Advisory Committee, Member
  • National Organization for Rare Disorders, Former Employee
  • Rare Disease Report, Contributing Writer
  • United States Pharmacopeial Convention Therapeutic Information and Formulary Support Expert Committee, Member
  • Affiliated with Epstein Health, LLC for funded research programs
  • Affiliated with Avalere Health, LLC as senior advisor
  • Affiliated with Banner Life Sciences as advisor
  • Participated in research on formulary coverage of orphan drugs that involved NORD receiving restricted funding from Novartis and CSL Behring for separate studies
  • Participated on technical expert panel for AHRQ-funded special issue of the Journal of General Internal Medicine; NORD received funding
  • Received funding from National Pharmaceutical Council for participating in ethics research involving formulary tiering processes


Person Type